Trial Profile
A phase 2b, multi-centre, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK390,957 in men with premature ejaculation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs UK 390957 (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Sponsors Pfizer
- 28 Aug 2006 Status change
- 19 Nov 2005 New trial record.